South Jersey pharma firm gets FDA approval for generic skin cream

Teligent Inc., a New Jersey-based specialty generic pharmaceutical company, announced Thursday it has received approval for its abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration. The FDA approved the ANDA for a skin disorder treatment called clobetasol propionate ointment from Teligent, a South Jersey specialty generic pharmaceutical company. The cream is used to treat a variety of skin disorders including eczema and psoriasis and for contact dermatitis caused by…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

This article summarizes the milestones in the development of delgocitinib leading to this first approval for the treatment of adults with atopic dermatitis. Clinical development of the topical formulation is also underway for alopecia areata, chronic hand eczema, discoid lupus erythematosus, inverse psoriasis and atopic dermatitis in several countries worldwide. Clinical development of an oral formulation of delgocitinib is also underway in Japan for the treatment of autoimmune disorders and hypersensitivity.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Conditions:   Down Syndrome;   Alopecia;   Atopic Dermatitis/Eczema;   Hidradenitis Suppurativa;   Vitiligo;   Psoriasis Intervention:   Drug: Tofacitinib Sponsors:   University of Colorado, Denver;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: We found lack of evidence to address our review question: for most of our interventions of interest, we found no eligible studies. The neurokinin 1 receptor (NK1R) antagonist serlopitant was the only intervention that we could assess. One study provided low-certainty evidence suggesting that serlopitant may reduce pruritus intensity when compared with placebo. We are uncertain of the effects of serlopitant on other outcomes, as certainty of the evidence is very low. More studies with larger sample sizes, focused on patients with CPUO, are needed. Healthcare professionals, patients, and other stakeholders may h...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Discussion: The results of our pilot study confirm the efficacy and tolerability of this new topical formulation in a real-life assessment and patients showed strong adherence to therapy. These promising results - still to be confirmed on a larger number of patients - emphasize the potential SEB has in controlling the chronic inflammation of seborrheic dermatitis. PMID: 31920359 [PubMed]
Source: Clinical, Cosmetic and Investigational Dermatology - Category: Dermatology Tags: Clin Cosmet Investig Dermatol Source Type: research
T helper (Th) type 17 and Th2 cells mediate psoriasis and eczema, respectively. Some dermatoses exhibit overlapping clinicopathologic features, and their immunopathology is relatively unexplored.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Tags: Dermatopathology Source Type: research
I've had a patch of flaky skin on and in my ears for sometime now, but only recently did this "condition" spread to my eyelids. Doctors have all kinds of names for this condition, including psoriasis, dermatitis, seborrheic dermatitis, eczema,  dandruff, and, when it gets into the eye lashes, blepharitis.The doctor may or may not tell you that the cause of these skin and eyebrow problems is often (1) a bacterial infection--because this makes us feel unclean and germy, or (2) an infection by Demodex folliculorum, a microscopic mite that lives in the hair follicles of the eyebrow and eats dead skin. The doctor...
Source: The Virtual Salt - Category: Neurology Authors: Source Type: blogs
This study demonstrated that O3 can activate cutaneous inflammasome in a redox dependent manner suggesting a possible role of this new pathway in pollution induced inflammatory skin conditions. PMID: 31778733 [PubMed - as supplied by publisher]
Source: Free Radical Biology and Medicine - Category: Biology Authors: Tags: Free Radic Biol Med Source Type: research
We present a case of a 58-year-old man who presented with 5 years of cutaneous symptoms and several months of fevers and night sweats, ultimately diagnosed as MF. Owing to diffuse CD30 positivity, he was a candidate for brentuximab vedotin, an antibody-drug conjugate medication that selectively targets the CD30 antigen. This resulted in an excellent therapeutic response.
Source: Journal of General Internal Medicine - Category: Internal Medicine Source Type: research
ConclusionPatch tests are a very useful diagnostic tool for patients with foot eczema with or without concomitant hand involvement.ResumenIntroducciónLa dermatitis de pies es un motivo frecuente de consulta en las Unidades de Alergia Cutánea.ObjetivosConocer las características demográficas, el diagnóstico y los alérgenos más frecuentemente implicados en los pacientes que han sido sometidos a las pruebas epicutáneas.Material y métodosEstudio observacional transversal en un Servicio de Dermatología con todos los pacientes estudiados con la batería ...
Source: Actas Dermo-Sifiliograficas - Category: Dermatology Source Type: research
This case report describes a series of patients who developed eczema after being treated for psoriasis with secukinumab.
Source: JAMA Dermatology - Category: Dermatology Source Type: research
More News: Biotechnology | Clobetasol | Dermatitis | Dermatology | Eczema | Food and Drug Administration (FDA) | Health Management | New Drug Applications | Pharmaceuticals | Psoriasis | Skin